JP2025513757A5 - - Google Patents
Info
- Publication number
- JP2025513757A5 JP2025513757A5 JP2024558028A JP2024558028A JP2025513757A5 JP 2025513757 A5 JP2025513757 A5 JP 2025513757A5 JP 2024558028 A JP2024558028 A JP 2024558028A JP 2024558028 A JP2024558028 A JP 2024558028A JP 2025513757 A5 JP2025513757 A5 JP 2025513757A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide
- phosphate
- seq
- salt
- dsrna agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263326770P | 2022-04-01 | 2022-04-01 | |
| US63/326,770 | 2022-04-01 | ||
| US202263326813P | 2022-04-02 | 2022-04-02 | |
| US63/326,813 | 2022-04-02 | ||
| PCT/US2023/065196 WO2023192977A2 (en) | 2022-04-01 | 2023-03-31 | Snca-targeting sirna compositions for treating snca-associated disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025513757A JP2025513757A (ja) | 2025-04-30 |
| JP2025513757A5 true JP2025513757A5 (enExample) | 2026-04-03 |
Family
ID=88203639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024558028A Pending JP2025513757A (ja) | 2022-04-01 | 2023-03-31 | ＳＮＣＡ関連疾患を処置するためのＳＮＣＡ標的化ｓｉＲＮＡ組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20250059541A1 (enExample) |
| EP (1) | EP4504938A2 (enExample) |
| JP (1) | JP2025513757A (enExample) |
| KR (1) | KR20240166577A (enExample) |
| CN (1) | CN119156448A (enExample) |
| AU (1) | AU2023241905A1 (enExample) |
| CA (1) | CA3254960A1 (enExample) |
| CL (1) | CL2024002960A1 (enExample) |
| CO (1) | CO2024012499A2 (enExample) |
| IL (1) | IL315594A (enExample) |
| MX (1) | MX2024011539A (enExample) |
| TW (1) | TW202407100A (enExample) |
| WO (1) | WO2023192977A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026085164A2 (en) | 2024-10-16 | 2026-04-23 | Alnylam Pharmaceuticals, Inc. | Snca irna formulations and methods of use thereof |
-
2023
- 2023-03-31 EP EP23782086.5A patent/EP4504938A2/en active Pending
- 2023-03-31 AU AU2023241905A patent/AU2023241905A1/en active Pending
- 2023-03-31 WO PCT/US2023/065196 patent/WO2023192977A2/en not_active Ceased
- 2023-03-31 JP JP2024558028A patent/JP2025513757A/ja active Pending
- 2023-03-31 KR KR1020247036545A patent/KR20240166577A/ko active Pending
- 2023-03-31 CA CA3254960A patent/CA3254960A1/en active Pending
- 2023-03-31 MX MX2024011539A patent/MX2024011539A/es unknown
- 2023-03-31 IL IL315594A patent/IL315594A/en unknown
- 2023-03-31 TW TW112112698A patent/TW202407100A/zh unknown
- 2023-03-31 CN CN202380038419.3A patent/CN119156448A/zh active Pending
-
2024
- 2024-09-13 CO CONC2024/0012499A patent/CO2024012499A2/es unknown
- 2024-09-27 US US18/898,882 patent/US20250059541A1/en active Pending
- 2024-10-01 CL CL2024002960A patent/CL2024002960A1/es unknown
- 2024-12-12 US US18/978,602 patent/US20250115911A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022515193A5 (enExample) | ||
| CN110846316B (zh) | 在基因沉默中具有降低的脱靶效应的una寡聚物 | |
| JP2020533334A5 (enExample) | ||
| JP2019518037A (ja) | Ｂ型肝炎感染症治療用のＰＡＰＤ５又はＰＡＰＤ７のｍＲＮＡ減少用核酸分子 | |
| PT788366E (pt) | Urilizacao de oligonucleotidos substituidos em 2' para a regulacao no sentido de reduzir da expressao de genes | |
| JP2019525918A5 (enExample) | ||
| US10933081B2 (en) | Myostatin iRNA compositions and methods of use thereof | |
| US9481887B2 (en) | DNA aptamers for promoting remyelination | |
| JP2023523993A5 (enExample) | ||
| WO2024008114A1 (zh) | 用于抑制补体因子B表达的siRNA、其缀合物和药物组合物及其用途 | |
| EP4396351A1 (en) | Compounds and methods for reducing dmpk expression | |
| JP2023511434A5 (enExample) | ||
| JP2024544532A (ja) | Ｈｂｖの処置のための医薬組合せ | |
| JP2025513757A5 (enExample) | ||
| JP2000514095A (ja) | 生物学的利用能を向上するためのオリゴヌクレオチド | |
| AU2024220263A1 (en) | Allele-selective compounds and methods for modulating huntingtin expression | |
| RU2024129253A (ru) | КОМПОЗИЦИИ SNCA-НАПРАВЛЕННЫХ миРНК ДЛЯ ЛЕЧЕНИЯ SNCA-АССОЦИИРОВАННОГО ЗАБОЛЕВАНИЯ | |
| JP2023545041A (ja) | Ｄｍｄ患者におけるエクソン５１スキッピングによるジストロフィンレスキューのためのオリゴマー化合物 | |
| EP3914713A1 (en) | Nrl expression reducing oligonucleotides, compositions containing the same, and methods of their use | |
| WO2025140551A1 (en) | COMPOSITIONS AND METHODS FOR TREATING NaV1.7 (SCN9A) -ASSOCIATED DISORDERS | |
| WO2026080897A1 (en) | Antisense oligonucleotides for the treatment of chronic pain | |
| TW202508606A (zh) | 修飾的核苷類似物及其用途與含核苷酸類似物的雙股寡核苷酸及其用途 | |
| US20230212572A1 (en) | Guanosine Analogues for Use in Therapeutics Polynucleotides | |
| WO2025190276A1 (zh) | 抑制dmpk表达的多核苷酸分子及其用途 | |
| WO2025043202A1 (en) | Compounds and methods for reducing atn1 expression |